2형 당뇨병의 새로운 치료

키워드

참고문헌 (41)

1. The Diabetes Control and Complications Trial Research Group, "The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin- dependent diabetes mellitus", N Engl J Med, 329, pp.977~986 (1993)
2. "Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group", Lancet, 352, pp.837~853 (1998)
3. Nathan DM, "Clinical practice. Initial management of glycemia in type 2 diabetes mellitus", N Engl J Med, 347, pp.1342~1349 (2002)
4. Bagg W, "The effects of intensive glycaemic control on body composition in patients with type 2 diabetes", Diabetes Obes Metab, 3, pp.410~416 (2001)
5. Srinivasan BT, "Recent advances in the management of type 2 diabetes mellitus: a review", Postgrad Med J, 84, pp.524~531 (2008)
6. Baggio LL, "Biology of incretins: GLP-1 and GIP", Gastroenterology, 132, pp.2131~2157 (2007)
7. Park IB, "New and emerging drugs in type 2 diabetes", Korean J Int Med, 72, pp.446~450 (2007)
8. Holst JJ, "Glucagonlike peptide 1: a newly discovered gastrointestinal hormone", Gastroenterology, 107, pp.1848~1855 (1994)
9. Drucker DJ, "Enhancing incretin action for the treatment of type 2 diabetes", Diabetes Care, 26, pp.2929~2940 (2003)
10. Holst JJ, "Enteroglucagon", Annu Rev Physiol, 59, pp.257~271 (1997)
11. Green DE, "New therapies for diabetes", Clin Cornerstone, 8, pp.58~63 (2007)
12. Eng J, "Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas", J Biol Chem, 267, pp.7402~7405 (1992)
13. Thorens B, "Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor", Diabetes, 42, pp.1678~1682 (1993)
14. DeFronzo RA, "Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes", Diabetes Care, 28, pp.1092~1100 (2005)
15. Buse JB, "Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes", Diabetes Care, 27, pp.2628~2635 (2004)
16. Kendall DM, , Diabetes Care, 28, pp.1083~1091 (2005)
17. Zinman B, "The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial", Ann Intern Med, 146, pp.477~485 (2007)
18. Amori RE, "Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta- analysis", JAMA, 298, pp.194~206 (2007)
19. Heine RJ, "Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes: A Randomized Trial", Ann Intern Med, 143, pp.559~569 (2005)
20. Nauck MA, "A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study", Diabetologia, 50, pp.259~267 (2007)
21. Elbrond B, "Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects", Diabetes Care, 25, pp.1398~1404 (2002)
22. Juhl CB, "Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes", Diabetes, 51, pp.424~429 (2002)
23. Vilsboll T, "Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes", Diabetes Care, 30, pp.1608~1610 (2007)
24. Deacon CF, "Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon- like peptide 1 in the anesthetized pig", Diabetes, 47, pp.764~769 (1998)
25. Herman GA, "Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes", J Clin Endocrinol Metab, 91, pp.4612~4619 (2006)
26. Pratley RE, "Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes", Curr Med Res Opin, 23, pp.919~931 (2007)
27. Aschner P, "Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes", Diabetes Care, 29, pp.2632~2637 (2006)
28. Charbonnel B, "Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone", Diabetes Care, 29, pp.2638~2643 (2006)
29. Rosenstock J, "Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double- blind, placebo-controlled, parallel-group study", Clin Ther, 28, pp.1556~1568 (2006)
30. Want LL, "Pramlintide: A new tool in diabetes management", Curr Diab Rep, 6, pp.344~349 (2006)
31. Jones MC, "Therapies for diabetes: pramlintide and exenatide", Am Fam Physician, 75, pp.1831~1835 (2007)
32. Ratner RE, "Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial", Diabet Med, 21, pp.1204~1212 (2004)
33. Edelman SV, "Pramlintide in the treatment of diabetes", Int J Clin Pract, 60, pp.1647~1653 (2006)
34. Pi-Sunyer FX, "Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial", JAMA, 295, pp.761~775 (2006)
35. Van Gaal LF, "Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study", Lancet, 365, pp.1389~1397 (2005)
36. Despres JP, "Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia", N Engl J Med, 353, pp.2121~2134 (2005)
37. Scheen AJ, "Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study", Lancet, 368, pp.1660~1672 (2006)
38. Christensen R, "Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials", Lancet, 370, pp.1706~1713 (2007)
39. Pories WJ, "Bariatric Surgery: Risks and Rewards", J Clin Endocrinol Metab, 93(11), pp.89S~96S (2008)
40. Buchwald H, "Weight and Type 2 Diabetes after Bariatric Surgery: Systematic Review and Meta-analysis", Am J Med, 122, pp.248~256 (2009)
41. Laferrere B, "Effect of Weight Loss by Gastric Bypass Surgery Versus Hypocaloric Diet on Glucose and Incretin Levels in Patients with Type 2 Diabetes", J Clin Endocrinol Metab, 93, pp.2479~2485 (2008)

관련 논문AI추천